trending Market Intelligence /marketintelligence/en/news-insights/trending/3B5eO8tjUEu1mR_GghdLjg2 content esgSubNav
In This List

Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Emergent BioSolutions Inc. received approval from the German Federal Ministry of Health unit Paul-Ehrlich-Institut for its large-scale manufacturing facility in Lansing, Mich., for the anthrax vaccine BioThrax.

The approval enables Emergent to market BioThrax in Germany.

BioThrax is the only anthrax vaccine licensed by the Paul-Ehrlich-Institut for pre-exposure prophylaxis of anthrax disease. It is also the only anthrax vaccine licensed by the U.S. FDA for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.